| Revenue growth | FY26 revenue up 6.4% YoY; Q4FY26 revenue up 11.2% YoY. |
|---|---|
| Margins | FY26 Gross Margin expanded 310bps to 59.7%; EBITDA margin up 140bps to 19%. |
| Demand visibility | Growth led by Ex-US markets; US stable but seasonally impacted. |
| Management confidence | Confident in long-term sustainable growth despite external headwinds. |
Growth
FY26 EBITDA grew 15.3% to ₹9,253m; Operational EPS rose 50% to ₹56.2. Ex-US markets grew 21% YoY.
Outlook
Aims for ~$400m North America revenue by FY28; growth recovery expected in H2FY27 with new launches.
Risks
US business impacted by weak flu season and slower-than-expected quota allocation for controlled substances.
Earnings Call filed with BSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,088.70
- Market cap
- ₹10,035 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.4×Sector 47.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Business Update
Strides Pharma Science received a USFDA Establishment Inspection Report (EIR) for its Bengaluru facility. This confirms the successful closure of the recent cGMP inspection.
Strides Pharma Science Annual General Meeting
Strides Pharma Science Ltd held its 35th Annual General Meeting on August 14, 2026. The meeting transacted ordinary and special business items.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science Results Update
Strides Pharma Science reported a 13% YoY revenue growth to ₹1,265.4 Crore for Q1FY27. EBITDA grew 5.4% to ₹229.8 Crore despite geopolitical cost disruptions.
- Value
- ₹1,265 Cr